≥98% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Information
INCB054329 INCB054329 (INCB-054329, INCB-54329) is a structurally distinct bromodomain and extraterminal domain (BET) inhibitor with IC50 values of 44 nM, 5 nM, 9 nM, 1 nM, 28 nM, 3 nM, 119 nM and 63 nM for BRD2-BD1, BRD2-BD2, BRD3-BD1, BRD3-BD2, BRD4-BD1, BRD4-BD2, BRDT-BD1 and BRDT-BD2, respectively.
Targets
BRD3-BD2 ; BRD4-BD2 ; BRD2-BD2 ; BRD3-BD1 ; BRD4-BD1 31176,1 nM; 3 nM; 5 nM; 9 nM; 28 nM
In vitro
INCB054329 shows no significant inhibitory activity against 16 non-BET bromodomains at 3 μM. In a panel of 32 hematologic cancer cell lines derived from acute myeloid leukemia, non-Hodgkin lymphoma, and multiple myeloma, the median 50% growth inhibition (GI50) value of INCB054329 is 152 nM (range, 26-5000 nM). In contrast to tumor cell lines, the GI50 value against T cells isolated from non-diseased donors stimulated ex vivo with IL-2 is 2.435 μM. Growth inhibition correlates with a concentration-dependent accumulation of cells in the G1 phase of the cell cycle. INCB054828 is also a selective kinase inhibitor of the FGFR 1, 2, and 3. In myeloma cell lines, treatment with INCB054329 inhibits expression of c-MYC and induced HEXIM1. In both AML and lymphoma cell lines, INCB054329 induces apoptosis consistent with increased expression of pro-apoptotic regulators. INCB054329 reduces expression of Homologous recombination (HR) components and co-operatively reduces cell growth and increases DNA damage and apoptosis induced by PARPi and cisplatin.
In vivo
INCB054329 exhibits high clearance in mice resulting in a short half-life. At exposures that effectively suppressed c-MYC, INCB054329 is found to be efficacious and well tolerated in both the KMS-12-BM and MM1.S xenograft models. oral administration of INCB054329 inhibits tumor growth in several models of hematologic cancers.
Cell Research(from reference)
Cell lines：Myeloma, AML, DLBCL cells
Incubation Time：72 h
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organoheterocyclic compounds |
| 分類 | Benzoxazines |
| Subclass | Not available |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Benzoxazines |
| Alternative Parents | Benzimidazoles Alkyl aryl ethers Pyridines and derivatives N-substituted imidazoles Benzenoids Isoxazoles Heteroaromatic compounds Ureas Oxacyclic compounds Azacyclic compounds Organonitrogen compounds Organic oxides Hydrocarbon derivatives |
| Molecular Framework | Aromatic heteropolycyclic compounds |
| Substituents | Benzoxazine - Benzimidazole - Alkyl aryl ether - Benzenoid - Pyridine - N-substituted imidazole - Azole - Heteroaromatic compound - Imidazole - Isoxazole - Urea - Ether - Oxacycle - Azacycle - Organic nitrogen compound - Hydrocarbon derivative - Organic oxide - Organic oxygen compound - Organooxygen compound - Organonitrogen compound - Aromatic heteropolycyclic compound |
| 説明 | This compound belongs to the class of organic compounds known as benzoxazines. These are organic compounds containing a benzene fused to an oxazine ring (a six-membered aliphatic ring with four carbon atoms, one oxygen atom, and one nitrogen atom). |
| External Descriptors | Not available |
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | 日付 | 商品 |
|---|---|---|---|
 F2625086 | Certificate of Analysis | Jul 06, 2026 | I414154 |
| D23181277 | Certificate of Analysis | Mar 13, 2023 | I414154 |
| D23181293 | Certificate of Analysis | Mar 13, 2023 | I414154 |
| D23181294 | Certificate of Analysis | Mar 13, 2023 | I414154 |
| D23181297 | Certificate of Analysis | Mar 13, 2023 | I414154 |
| D23181302 | Certificate of Analysis | Mar 13, 2023 | I414154 |
| D23181342 | Certificate of Analysis | Mar 13, 2023 | I414154 |
| D23181357 | Certificate of Analysis | Mar 13, 2023 | I414154 |
| D23181358 | Certificate of Analysis | Mar 13, 2023 | I414154 |
| D23181362 | Certificate of Analysis | Mar 13, 2023 | I414154 |
| D23181392 | Certificate of Analysis | Mar 13, 2023 | I414154 |
| D23181395 | Certificate of Analysis | Mar 13, 2023 | I414154 |
| D23181484 | Certificate of Analysis | Mar 13, 2023 | I414154 |
| 溶解度 | Solubility (25°C) In vitro DMSO: 70 mg/mL (200.94 mM); Ethanol: 70 mg/mL (200.94 mM); Water: ˂1 mg/mL |
|---|---|
| DMSO（mg / mL） 最大溶解度 | 70 |
| DMSO（mM） 最大溶解度 | 200.941554713515 |
| 水（mg / mL） 最大溶解度 | ˂1 |
| 分子量 | 348.400 g/mol |
| XLogP3 | 1.900 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 2 |
| Exact Mass | 348.122 Da |
| Monoisotopic Mass | 348.122 Da |
| Topological Polar Surface Area | 80.500 Ų |
| Heavy Atom Count | 26 |
| Formal Charge | 0 |
| Complexity | 561.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |
